Immunovant (IMVT) Liabilities and Shareholders Equity (2018 - 2026)

Immunovant has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $957.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 23.29% year-over-year to $957.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 billion (up 41.31% YoY), and the FY2026 full-year result was $957.0 million, up 23.29% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $957.0 million, down from $1.1 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.1 billion in Q4 2025, with the low at $292.1 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $578.9 million across 5 years, with a median of $515.7 million in 2024.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity tumbled 40.83% — and 2025, when it soared 150.01%.
• Immunovant's Liabilities and Shareholders Equity stood at $456.2 million in 2022, then soared by 55.94% to $711.4 million in 2023, then plunged by 40.83% to $420.9 million in 2024, then soared by 150.01% to $1.1 billion in 2025, then declined by 9.06% to $957.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $957.0 million (Q1 2026), $1.1 billion (Q4 2025), and $583.0 million (Q3 2025), per Business Quant data.